Who is sponsoring NCT06291779?

NCT06291779 is sponsored by Ho-Seong Han.

What drugs are being tested in NCT06291779?

Interventions in NCT06291779: Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio.

What condition does NCT06291779 study?

NCT06291779 studies Pancreas Cancer, Diagnosis.

Is NCT06291779 still recruiting?

NCT06291779 is currently status unknown. Last updated 4 March 2024.

Last reviewed 2024-03-04 · How we verify

NCT06291779

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diagnosis of Pancreatic Cancer by Purine Metabolite (Hypoxanthine, Xanthine) in Urine

Status unknown Last updated 4 March 2024

What this trial tests

trial testing Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio in Pancreas Cancer in 120 participants. Status unknown.

Timeline

30 November 2022

Primary endpoint
26 February 2024

31 May 2024

Quick facts

Lead sponsor	Ho-Seong Han
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	120
Start date	30 November 2022
Primary completion	26 February 2024
Estimated completion	31 May 2024
Sites	1 location across South Korea

Drugs / interventions tested

Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio

Conditions studied

Pancreas Cancer — all drugs for Pancreas Cancer →
Diagnosis — all drugs for Diagnosis →

Sponsor

Ho-Seong Han

Who can join

Adults 18 to 80, any sex, with Pancreas Cancer or Diagnosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

* This study aim to develope a diagnostic method of pancreatic cancer by using a reagent for analyzing purine metabolite (Hypoxanthine, Xanthine) in urine. * It is safe and cost effective compare to radiologic or blood test. It can be used for initial screening test for healty population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pancreas Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07230509 — Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate · Phase 2 · recruiting
NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07132541 — Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06291779 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ho-Seong Han
Last refreshed: 4 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06291779.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing